4C Medical Technologies secured more than $8 million in an equity offering it hopes will reach the $20 million mark.
The Maple Grove, Minn.-based company raised nearly $8.2 million in the offering, with $11.8 million remaining to be sold, according to an SEC Form D filed today.
Forty-five unnamed investors have contributed to the offering. The first sale came Sept. 25.
In September 2018, 4C Medical announced that it raised a $17 million Series A round for the AltaValve transcatheter mitral valve replacement device it’s developing.
The AltaValve TMVR is designed to preserve the native mitral valve and left ventricle by using supra-annular, atrial-only fixation.
